Radiation Syndrome
1. Zareen Khan
2. Ganesh Jadhav
3. Vaishnavi Murugan
4. Nashreen Mohamed
5. Mohammad Adil
6. Musaeva Begaiym
(Student, International Medical Faculty, Osh State University, Kyrgyzstan)
(Student, International Medical Faculty, Osh State University, Kyrgyzstan)
(Student, International Medical Faculty, Osh State University, Kyrgyzstan)
(Student, International Medical Faculty, Osh State University, Kyrgyzstan)
(Student, International Medical Faculty, Osh State University, Kyrgyzstan)
(Teacher, International Medical Faculty, Osh State University, Kyrgyzstan)
Abstract
Radiation syndrome represents a complex of clinical manifestations resulting from whole-body or partial-body exposure to ionizing radiation. Depending on the dose, duration, and rate of exposure, radiation injury may present as either acute radiation syndrome (ARS) or chronic radiation syndrome (CRS). Acute radiation syndrome develops following a high-dose exposure over a short period, commonly observed in nuclear accidents, radiotherapy mishaps, or industrial exposures. Chronic radiation syndrome, in contrast, arises from prolonged exposure to lower doses of radiation, often seen in occupational settings or contaminated environments. This article reviews the etiology, pathophysiology, clinical features, diagnostic approaches, and outcomes of both acute and chronic radiation syndromes, emphasizing their differences, progression, and long-term implications for patient health.
Introduction
Introduction to the literature review
This review surveys how radiation exposure and its blological consequences have been understood and evaluated across studies published from 2012 to 2021, with a focus on radiation syndrome and its broader systemic implications. The discussion unfolds chronologically, tracing shifts in conceptual frameworks from. Conventional target theory toward recognition of organism-wide and molecular responses that shape treatment outcomes, safety, and personalized risk assessment.
(Pouget et al, 2012) foregrounds the shift from a strictly target-based view of radiation damage to recognizing off-target effects, including bystander and abscopal responses, as integral to understanding radiotherapy and radioprotection. The authors argue that whole-organism evaluation. Is essential and that mechanisms such as radical species release, DNA damage responses, repair processes, and immune activation contribute to proinflammatory signaling and systemic resporises This perspective sets up a paradigm where cellular components beyond the directly irradiated region influence clinical outcomes and safety profiles, suggesting opportunities to exploit these effects at higher doses in combination therapies while also acknowledging that traditional risk estimates for radiation-induced cancer and hereditary effects remain unchanged. The article thus introduces a broader, systems-level lens for interpreting radiobiological effects and their Implications for risk-benefit analyses in clinical practice.
(V. Gorbunov & Sharma, 2015) extend the discussion to hematopoietic acute radiation syndrome
(hARS) by detailing protracted oxidative alterations following high-dose total body irradiation. They describe how oxidative damage to biomolecules drives cell death and progressive tissue dysfunction, with hematopoietic and lymphoid compartments particularly affected. The authors emphasize a two-hit cascade: initial direct injury, followed by bacterial translocation and sepsis, which amplifies oxidative stress and tissue damage. Central to this narrative is the role of redox mechanisms in modulating radiation-induced molecular alterations and the contribution of radioresistant stromal cells to prolonged responses and septicemia. This work highlights temporal dynamics and organ-system vulnerability, framing hARS as a cascade influenced by sustained oxidative stress and interrelated cellular interactions.
(K. Singh et al., 2015) provide a practical clinical and policy-oriented perspective by characterizing medical countermeasures for radiation exposure and related injuries. They delineate the subsyndromes of ARS-hematopoietic, Gl, and neurovascular-and describe how dose, exposure characteristics, and tissue sensitivity shape clinical trajectories. The narrative outlines the prodromal, latent, and manifest phases and discusses radioprotectors, mitigators, and repair-promoting treatments, along with radionuclide eliminators used in internal contamination scenarios. This work situates countermeasure development within regulatory and stockpile contexts, underscoring translational considerations for preparedness and acute management.
(Dainiak et al., 2015) address radiological and nuclear terrorism as an oncologic emergency. Emphasizing early dose estimation, triage, and clinical monitoring. They outline the manifest illness phase, prodromal signs, and the importance of timely CBC monitoring to track evolving cytopenias and immune dysfunction. The authors highlight the clinical heterogeneity of radiation illness and the necessity of recognizing radiation toxicity in patients presenting with gastrointestinal and systemic symptoms after exposure. This work reinforces practical imperatives for emergency response, diagnostic tracking, and dose-informed clinical decision-making in acute radiological events.
(Subedi et al., 2021) shift the focus toward molecular predictors of radiosensitivity by reviewing lonizing-radiation-induced changes in the human proteome and their association with radiosensitivity. They discuss how individual variability in adverse effects-ranging from inflammation to fibrosis and cognitive decline-limits treatment efficacy and quality of life for a subset of patients. The review surveys genetic and proteomic approaches to identifying radiosensitive individuals, highlighting the potential of protein biomarkers to tailor radiation therapy and risk assessment beyond genetic syndromes such as Ataxia-Telangiectasia and Fanconi anemia. This article foregrounds personalization, suggesting that proteomic signatures may better reflect cellular states relevant to radiation response than transcriptomic data alone.
Together, these works trace a trajectory from conceptual broadening of radiobiology to practical strategies for prediction, prevention, and managerment of radiation-associated syndromes. They collectively illustrate how oxidative stress, immune activation, and systemic signaling intersect with organ-specific damage, shaping both treatment planning and emergency response. The progression also signals an enduring need for integrating biomarker discovery and personalized risk assessment into clinical and public health strategies for radiation exposure.
Methods
This article is based on a comprehensive review of classical medical textbooks of radiology, hematology, and occupational medicine, along with peer-reviewed clinical studies and historical reports of radiation exposure incidents. Data were collected from documented cases of nuclear accidents, medical radiation exposure, and occupational radiation monitoring programs. Clinical manifestations were analyzed according to radiation dose ranges, organ system involvement, and temporal progression of symptoms. Comparative evaluation was performed between acute and chronic forms to highlight diagnostic criteria, clinical stages, and prognostic indicators. Emphasis was placed on human observational studies and long-term follow-up reports to ensure clinical relevance.
Results
Acute Radiation Syndrome (ARS)
Acute radiation syndrome occurs following exposure to ionizing radiation exceeding approximately 1 Gy within a short time frame, typically minutes to hours. The severity of ARS correlates directly with the absorbed dose.
ARS progresses through four characteristic stages:
Prodromal stage
Occurs within minutes to days after exposure. Symptoms include nausea, vomiting, anorexia, fatigue, headache, and diarrhea. The intensity of symptoms reflects the radiation dose received.
Latent stage
A temporary period of apparent clinical improvement lasting from hours to weeks. Cellular damage continues at the tissue level despite minimal symptoms.
Manifest illness stage
This stage reflects organ system failure and is classified into distinct clinical syndromes:
Hematopoietic syndrome (1–6 Gy): bone marrow suppression leading to leukopenia, thrombocytopenia, anemia, infections, and hemorrhage.
Gastrointestinal syndrome (6–10 Gy): severe diarrhea, dehydration, electrolyte imbalance, sepsis, and intestinal mucosal necrosis.
Neurovascular (cerebrovascular) syndrome (>10–20 Gy): confusion, seizures, hypotension, coma, and death within days.
Recovery or death
Survival depends on dose, supportive care, and stem cell recovery. Hematopoietic recovery may take months in survivors.
Chronic Radiation Syndrome (CRS)
Chronic radiation syndrome develops after long-term exposure to low or moderate doses of ionizing radiation, usually below the threshold for acute illness but sufficient to cause cumulative biological damage. CRS often manifests after years of occupational exposure or environmental contamination.
Key clinical features include:
Persistent fatigue and weakness
Neurovegetative disturbances (irritability, sleep disorders, memory impairment)
Progressive bone marrow suppression
Endocrine dysfunction
Immunodeficiency
Increased risk of malignancies
Unlike ARS, CRS develops insidiously and lacks clearly defined stages. Symptoms are often nonspecific and progress gradually, making early diagnosis challenging.
Laboratory findings in CRS frequently show mild to moderate cytopenias, reduced lymphocyte counts, and impaired immune responses. Long-term follow-up reveals increased incidence of leukemia, thyroid cancer, and solid tumors.
Discussion
Radiation syndrome remains a significant medical concern despite advancements in radiation safety and monitoring. The contrasting presentations of acute and chronic radiation syndromes underscore the importance of exposure dose, duration, and biological tissue sensitivity. Acute radiation syndrome is characterized by rapid onset and dose-dependent organ failure, requiring immediate medical intervention and supportive care. Advances in hematopoietic growth factors, bone marrow transplantation, and infection control have improved survival rates in moderate ARS cases.
Chronic radiation syndrome poses a different challenge due to its slow progression and nonspecific symptoms. Occupational exposure remains the most common cause, highlighting the importance of strict radiation safety protocols, dosimetric monitoring, and periodic medical surveillance. Early recognition of CRS can prevent progression to irreversible organ damage and malignancy.
From a public health perspective, both forms emphasize the need for preparedness in nuclear and radiological emergencies, as well as long-term monitoring of exposed populations. The psychological and social impacts of radiation exposure should also be considered, as anxiety and stress-related disorders frequently accompany chronic radiation illness.
References
Pouget, J. P., Georgakilas, A., & Ravanat, J. L., 2012. Targeted and Off-Target (Bystander and Abscopal) Effects of Radiation Therapy: Redox Mechanisms and Risk/Benefit Analysis. [PRE]
V. Gorbunov, N. & Sharma, P., 2015. Protracted Oxidative Alterations in the Mechanism of Hematopoietic Acute Radiation Syndrome, ncbi.nlm.nih.gov
K. Singh, V., L.P. Romaine, P., & M. Seed, T., 2015, Medical Countermeasures for Radiation Exposure and Related Injuries: Characterization of Medicines, FDA Approval Status and Inclusion into the Strategic National Stockpile. ncbi.nlm.nih.gov
Dainiak, N., E. Goans, R., J. Iddins, C., & Case, C., 2015. Radiological and Nuclear Terrorism: The Oncologic Emergency Response. ncbi.nlm.nih.gov
Subedi, P., Gomolka, M., Moerti, S., & Dietz, A., 2021. Ionizing Radiation Protein Biomarkers in Normal Tissue and Their Correlation to Radiosensitivity: A Systematic Review, ocbi.nlm.nih.gov